AVEO Pharmaceuticals, Inc. (AVEO)

[stockguard]

Too much risk for this play, out.......

$AVEO Oncology Shifts TIVO-3 Topline Data for Renal Cancer to Q4 2018 - Stock Slumps 32% After-Hours

04:39 PM EDT, 07/16/2018 (MT Newswires) -- AVEO Oncology (AVEO) said on Monday it now expects to report TIVO-3 topline data in Q4 of 2018 due to the progression-free survival events (PFS) events occurring slower than forecasted, combined with some patients being removed from the PFS event count, which often occurs once the data cleaning and review process is initiated.

Prior to reporting data, Aveo said it plans to announce when 255 PFS events have occurred and topline data analysis for the trial has been initiated.

The company had expected to report topline data from the TIVO-3 trial, its phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma, 6-8 weeks after the trial records 255 PFS events.

Price: 1.93, Change: -0.92, Percent Change: -32.28

http://www.mtnewswires.com

July 16, 2018
4:38 pm ET
*Aveo Pharma 8-K Shows Warrant Deal With Computershare, Computershare Trust For Purchase Of 2M Shares Of Common Stock Related To Terms Of Stipulation Of Settlement OF Securities Class Action Suit
Benzinga

July 03, 2018
7:45 am ET
*AVEO Pharmaceuticals Received Notice From Novartis On Jun. 29th Of A Termination Of The AV-380 License Agreement Dated August 13, 2015; Termination Will Be Effective Aug. 28 And Will Not Impact Co.'s Cash Guidance